{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:06:45Z","timestamp":1778108805208,"version":"3.51.4"},"reference-count":222,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_162552\/1"],"award-info":[{"award-number":["310030_162552\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bulgarian-Swiss Research Program","award":["IZEBZO_142967"],"award-info":[{"award-number":["IZEBZO_142967"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00005-016-0422-x","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T10:37:48Z","timestamp":1474022268000},"page":"215-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Use and Therapeutic Potential of IVIG\/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations"],"prefix":"10.2478","volume":"65","author":[{"given":"Peter J.","family":"Sp\u00e4th","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von Gunten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"422_CR2","first-page":"CD001090","volume":"9","author":"MM Alejandria","year":"2013","unstructured":"Alejandria MM, Lansang MA, Dans LF et al (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 9:CD001090","journal-title":"Cochrane Database Syst Rev"},{"key":"422_CR3","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.1300261","volume":"192","author":"E Aleyd","year":"2014","unstructured":"Aleyd E, van Hout MW, Ganzevles SH et al (2014) IgA Enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fc\u03b1 receptor I. J Immunol 192:2374\u20132383","journal-title":"J Immunol"},{"key":"422_CR4","first-page":"162","volume":"5","author":"W Al-Herz","year":"2014","unstructured":"Al-Herz W, Bousfiha A, Casanova JL et al (2014) Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 5:162","journal-title":"Front Immunol"},{"key":"422_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2003.09.045","volume":"112","author":"F Altznauer","year":"2003","unstructured":"Altznauer F, von Gunten S, Sp\u00e4th P et al (2003) Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 112:1185\u20131190","journal-title":"J Allergy Clin Immunol"},{"key":"422_CR6","unstructured":"Anonymous (1990) Beipackzettel IgAbulin\u2014Immunglobulin A Konzentat Human zur peroralen Anwendung\u2014Prophylaxe der necrotisierenden Enterocolitis\u2014Package insert IgAbulin\u2014Prophylaxis of necrotizint eneterocolitis"},{"key":"422_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0338-4535(75)80013-4","volume":"18","author":"R Audran","year":"1975","unstructured":"Audran R, Pejaudier L, Steinbuch M (1975) Preparation of immunoglobulins G, A, M (IgGAM) for therapeutic use. Conditions for enrichment in IgA or in IgM. Rev Fr Transfus Immunohematol 18:119\u2013135","journal-title":"Rev Fr Transfus Immunohematol"},{"key":"422_CR8","first-page":"231","volume":"132C","author":"S Avrameas","year":"1981","unstructured":"Avrameas S, Guilbert B, Dighiero G (1981) Natural antibodies against tubulin, actin, myoglobulin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera and monoclonal immunoglobulins from multiple myeloma and Waldenstroem\u2019s macroglobulinemia may express similar antibody specifities. Ann Immunol 132C:231\u2013236","journal-title":"Ann Immunol"},{"key":"422_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/petr.12636","volume":"20","author":"F Az\u0131k","year":"2016","unstructured":"Az\u0131k F, Bayram C, Erko\u00e7o\u011flu M et al (2016) Comparison of prophylactic use of intravenous immunoglobulin versus Pentaglobin\u00ae in pediatric patients after hematopoietic stem cell transplantation. Pediatr Transplant 20:276\u2013283","journal-title":"Pediatr Transplant"},{"key":"422_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/mi.2011.36","volume":"4","author":"JE Bakema","year":"2011","unstructured":"Bakema JE, van Egmond M (2011) The human immunoglobulin A Fc receptor Fc[alpha]RI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 4:612\u2013624","journal-title":"Mucosal Immunol"},{"key":"422_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1053\/j.gastro.2010.12.005","volume":"140","author":"F Barone","year":"2011","unstructured":"Barone F, Vossenkamper A, Boursier L et al (2011) IgA-producing plasma cells originate from germinal centers that are induced by B-cell receptor engagement in humans. Gastroenterology 140:947\u2013956","journal-title":"Gastroenterology"},{"key":"422_CR12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V74.1.326.326","volume":"74","author":"M Basta","year":"1989","unstructured":"Basta M, Langlois P, Marques M et al (1989) High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74:326\u2013333","journal-title":"Blood"},{"key":"422_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","volume":"101","author":"J Bayry","year":"2003","unstructured":"Bayry J, Lacroix-Desmazes S, Carbonneil C et al (2003a) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758\u2013765","journal-title":"Blood"},{"key":"422_CR14","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1002\/art.11346","volume":"48","author":"J Bayry","year":"2003","unstructured":"Bayry J, Lacroix-Desmazes S, Delignat S et al (2003b) Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-\u03b1 present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48:3497\u20133502","journal-title":"Arthritis Rheum"},{"key":"422_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.amjmed.2005.06.028","volume":"118","author":"J Bayry","year":"2005","unstructured":"Bayry J, Lacroix-Desmazes S, Hermine O et al (2005) Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 118:1439\u20131440","journal-title":"Am J Med"},{"key":"422_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2141.2006.06245.x","volume":"135","author":"R Bazin","year":"2006","unstructured":"Bazin R, Lemieux R, Tremblay T (2006) Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 135:97\u2013100","journal-title":"Br J Haematol"},{"key":"422_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.autrev.2012.10.011","volume":"12","author":"S Ben Mkaddem","year":"2013","unstructured":"Ben Mkaddem S, Rossato E, Heming N et al (2013) Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun Rev 12:666\u2013669","journal-title":"Autoimmun Rev"},{"key":"422_CR18","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1172\/JCI44447","volume":"121","author":"J Benckert","year":"2011","unstructured":"Benckert J, Schmolka N, Kreschel C et al (2011) The majority of intestinal IgA+\u00a0and IgG+\u00a0plasmablasts in the human gut are antigen-specific. J Clin Invest 121:1946\u20131955","journal-title":"J Clin Invest"},{"key":"422_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2334-9-18","volume":"9","author":"D Ben-Nathan","year":"2009","unstructured":"Ben-Nathan D, Gershoni-Yahalom O, Samina I et al (2009) Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 9:18","journal-title":"BMC Infect Dis"},{"key":"422_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1749-6632.2000.tb05390.x","volume":"917","author":"I Berczi","year":"2000","unstructured":"Berczi I, Bertok L, Chow DA (2000) Natural immunity and neuroimmune host defense. Ann N Y Acad Sci 917:248\u2013257","journal-title":"Ann N Y Acad Sci"},{"key":"422_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/0003-4819-93-1-55","volume":"93","author":"MC Berger","year":"1980","unstructured":"Berger MC, Cupps TR, Fauci AS (1980) Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93:55\u201356","journal-title":"Ann Intern Med"},{"key":"422_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/BF01710530","volume":"21","author":"M Bitzan","year":"1993","unstructured":"Bitzan M, Klemt M, Steffens R et al (1993) Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection 21:140\u2013145","journal-title":"Infection"},{"key":"422_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00832.x","volume":"232","author":"U Blank","year":"2009","unstructured":"Blank U, Launay P, Benhamou M et al (2009) Inhibitory ITAMs as novel regulators of immunity. Immunol Rev 232:59\u201371","journal-title":"Immunol Rev"},{"key":"422_CR24","first-page":"1193","volume":"5","author":"C Blatrix","year":"1976","unstructured":"Blatrix C, Israel J, Reinert P et al (1976) The use of new immunoglobulin preparation, enriched in IgA and IgM (IgGAM) [article in French]. Nouv Presse Med 5:1193\u20131195","journal-title":"Nouv Presse Med"},{"key":"422_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0161-5890(01)00025-6","volume":"37","author":"M Boes","year":"2000","unstructured":"Boes M (2000) Role of natural and immune IgM antibodies in immune responses. Mol Immunol 37:1141\u20131149","journal-title":"Mol Immunol"},{"key":"422_CR26","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.aad5788","volume":"351","author":"ZA Bornholdt","year":"2016","unstructured":"Bornholdt ZA, Turner HL, Murin CD et al (2016) Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351:1078\u20131083","journal-title":"Science"},{"key":"422_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/jaut.2000.0472","volume":"16","author":"J-P Bouvet","year":"2001","unstructured":"Bouvet J-P, Stahl D, Rose S et al (2001) Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J Autoimmun 16:163\u2013172","journal-title":"J Autoimmun"},{"key":"422_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0003-9861(91)90266-L","volume":"284","author":"JK Brieland","year":"1991","unstructured":"Brieland JK, Fantone JC (1991) Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: effect of pH and iron saturation. Arch Biochem Biophys 284:78\u201383","journal-title":"Arch Biochem Biophys"},{"key":"422_CR29","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1186\/cc13028","volume":"17","author":"R Brunner","year":"2013","unstructured":"Brunner R, Rinner W, Haberler C et al (2013) Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and\/or myopathy in patients with multiple organ failure and SIRS\/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial. Crit Care 17:R213\u2013R213","journal-title":"Crit Care"},{"key":"422_CR30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"O Bruton","year":"1952","unstructured":"Bruton O (1952) Agammaglobulinemia. Pediatrics 9:722\u2013728","journal-title":"Pediatrics"},{"key":"422_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1067\/mai.2002.124999","volume":"109","author":"PJ Busse","year":"2002","unstructured":"Busse PJ, Razvi S, Cunningham-Rundles C (2002) Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109:1001\u20131004","journal-title":"J Allergy Clin Immunol"},{"key":"422_CR32","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.4049\/jimmunol.1301611","volume":"192","author":"IK Campbell","year":"2014","unstructured":"Campbell IK, Miescher S, Branch DR et al (2014) Therapeutic Effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol 192:5031\u20135038","journal-title":"J Immunol"},{"key":"422_CR33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/0167-5699(89)90268-5","volume":"10","author":"P Casali","year":"1989","unstructured":"Casali P, Notkins AL (1989) CD5+\u00a0B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 10:364\u2013368","journal-title":"Immunol Today"},{"key":"422_CR34","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1651-2227.1996.tb14231.x","volume":"85","author":"TH Casswall","year":"1996","unstructured":"Casswall TH, Hammarstr\u00f6m L, Veress B et al (1996) Oral IgA-IgG treatment of chronic non-specific diarrhoea in infants and children. Acta Paediatr 85:1126\u20131128","journal-title":"Acta Paediatr"},{"key":"422_CR35","doi-asserted-by":"publisher","first-page":"e26469","DOI":"10.1371\/journal.pone.0026469","volume":"6","author":"S Casulli","year":"2011","unstructured":"Casulli S, Top\u00e7u S, Fattoum L et al (2011) A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One 6:e26469","journal-title":"PLoS One"},{"key":"422_CR36","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.4049\/jimmunol.0804191","volume":"182","author":"Y Chen","year":"2009","unstructured":"Chen Y, Park YB, Patel E et al (2009) IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol 182:6031\u20136043","journal-title":"J Immunol"},{"key":"422_CR37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/infdis\/jis212","volume":"205","author":"EA Clutterbuck","year":"2012","unstructured":"Clutterbuck EA, Lazarus R, Yu LM et al (2012) Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 205:1408\u20131416","journal-title":"J Infect Dis"},{"key":"422_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/ja01207a034","volume":"68","author":"EJ Cohn","year":"1946","unstructured":"Cohn EJ, Strong SL, Hughes WL et al (1946) Preparation and properties of serum and plasma proteins. IV: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 68:459\u2013475","journal-title":"J Am Chem Soc"},{"key":"422_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molmed.2013.10.004","volume":"20","author":"RJ Commons","year":"2014","unstructured":"Commons RJ, Smeesters PR, Proft T et al (2014) Streptococcal superantigens: categorization and clinical associations. Trends Mol Med 20:48\u201362","journal-title":"Trends Mol Med"},{"key":"422_CR40","doi-asserted-by":"publisher","first-page":"E3544","DOI":"10.1073\/pnas.1310657110","volume":"110","author":"M Crispin","year":"2013","unstructured":"Crispin M, Yu X, Bowden TA (2013) Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci USA 110:E3544\u2013E3546","journal-title":"Proc Natl Acad Sci USA"},{"key":"422_CR41","doi-asserted-by":"publisher","first-page":"14960","DOI":"10.1073\/pnas.0903805106","volume":"106","author":"DM Czajkowsky","year":"2009","unstructured":"Czajkowsky DM, Shao Z (2009) The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc Natl Acad Sci USA 106:14960\u201314965","journal-title":"Proc Natl Acad Sci USA"},{"key":"422_CR42","unstructured":"Danziger-Isakov LH, Kohli T, Lazear R et al (2015) Implementation of evidence-based guidelines for cytomegalovirus prevention in pediatric solid organ transplantation [Abstract]. Am J Transplant 2-5-2015"},{"key":"422_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1172\/JCI110610","volume":"70","author":"DL Delacroix","year":"1982","unstructured":"Delacroix DL, Hodgson HJ, McPherson A et al (1982) Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile and saliva. J Clin Invest 70:230\u2013241","journal-title":"J Clin Invest"},{"key":"422_CR44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1537-2995.2011.03384.x","volume":"52","author":"JM Despotovic","year":"2012","unstructured":"Despotovic JM, Lambert MP, Herman JH et al (2012) RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 52:1126\u20131136","journal-title":"Transfusion"},{"key":"422_CR45","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1002\/ijc.30025","volume":"138","author":"SK Devarapu","year":"2016","unstructured":"Devarapu SK, Mamidi S, Ploger F et al (2016) Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors. Int J Cancer 138:6963\u20136973","journal-title":"Int J Cancer"},{"key":"422_CR46","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3892\/or.2015.4095","volume":"34","author":"M Diaz-Zaragoza","year":"2015","unstructured":"Diaz-Zaragoza M, Hernandez-Avila R, Viedma-Rodriguez R et al (2015) Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer. Oncol Rep 34:1106\u20131114","journal-title":"Oncol Rep"},{"key":"422_CR47","doi-asserted-by":"publisher","first-page":"26696","DOI":"10.1074\/jbc.M702751200","volume":"282","author":"JD Dimitrov","year":"2007","unstructured":"Dimitrov JD, Roumenina LT, Doltchinkova VR et al (2007a) Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J Biol Chem 282:26696\u201326706","journal-title":"J Biol Chem"},{"key":"422_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1365-3083.2006.01893.x","volume":"65","author":"JD Dimitrov","year":"2007","unstructured":"Dimitrov JD, Roumenina LT, Doltchinkova VR et al (2007b) Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins. Scand J Immunol 65:230\u2013239","journal-title":"Scand J Immunol"},{"key":"422_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.autrev.2008.03.016","volume":"7","author":"JD Dimitrov","year":"2008","unstructured":"Dimitrov JD, Lacroix-Desmazes S, Kaveri SV et al (2008) Insight into the mechanism of the acquired antibody auto-reactivity. Autoimmun Rev 7:410\u2013414","journal-title":"Autoimmun Rev"},{"key":"422_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4614-3461-0_16","volume":"750","author":"J Dimitrov","year":"2012","unstructured":"Dimitrov J, Pashov A, Vassilev T (2012) Antibody polyspecificity: what does it matter? Adv Exp Med Biol 750:213\u2013226","journal-title":"Adv Exp Med Biol"},{"key":"422_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-3083.2005.01568.x","volume":"61","author":"I Djoumerska","year":"2005","unstructured":"Djoumerska I, Tchorbanov A, Pashov A et al (2005) The autoreactivity of therapeutic intravenous immunoglobulin (IVIg) preparations depends on the fractionation methods used. Scand J Immunol 61:357\u2013363","journal-title":"Scand J Immunol"},{"key":"422_CR52","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/j.1742-4658.2010.07714.x","volume":"277","author":"IK Djoumerska-Alexieva","year":"2010","unstructured":"Djoumerska-Alexieva IK, Dimitrov JD, Voynova EN et al (2010) Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J 277:3039\u20133050","journal-title":"FEBS J"},{"key":"422_CR53","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2014.00224","author":"I Djoumerska-Alexieva","year":"2015","unstructured":"Djoumerska-Alexieva I, Roumenina L, Pashov A et al (2015) Intravenous immunoglobulin with enhanced polyspecificity improves survival in experimental sepsis and aseptic systemic inflammatory response syndromes. Mol Med. doi: 10.2119\/molmed.2014.00224","journal-title":"Mol Med"},{"key":"422_CR54","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1055\/s-0033-1363771","volume":"31","author":"A DU Akdag","year":"2014","unstructured":"DU Akdag A, Haque K, Dilli D et al (2014) Role of pentoxifylline and\/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis. Am J Perinatol 31:905\u2013912","journal-title":"Am J Perinatol"},{"key":"422_CR55","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nri2849","volume":"10","author":"MR Ehrenstein","year":"2010","unstructured":"Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10:778\u2013786","journal-title":"Nat Rev Immunol"},{"key":"422_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198807073190101","volume":"319","author":"MM Eibl","year":"1988","unstructured":"Eibl MM, Wolf HM, F\u00fcrnkranz H et al (1988) Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA\u2013IgG feeding. N Engl J Med 319:1\u20137","journal-title":"N Engl J Med"},{"key":"422_CR57","doi-asserted-by":"publisher","first-page":"e0003501","DOI":"10.1371\/journal.pntd.0003501","volume":"9","author":"M El-Ekiaby","year":"2015","unstructured":"El-Ekiaby M, Vargas M, Sayed M et al (2015) Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. PLoS Negl Trop Dis 9:e0003501","journal-title":"PLoS Negl Trop Dis"},{"key":"422_CR58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF01745575","volume":"65","author":"B Emmerich","year":"1987","unstructured":"Emmerich B, Hiller E, Woitinas F et al (1987) Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin. Kiln Wochenschr 65:369\u2013372","journal-title":"Kiln Wochenschr"},{"key":"422_CR59","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s001050051143","volume":"51","author":"AH Enk","year":"2000","unstructured":"Enk AH, Knop J (2000) Successful management of systemic lupus erythematosus with IgM enriched immunoglobulins [article in German]. Hautarzt 51:416\u2013418","journal-title":"Hautarzt"},{"key":"422_CR60","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.1994.tb13253.x","volume":"396","author":"C Fast","year":"1994","unstructured":"Fast C, Rosegger H (1994) Necrotizing enterocolitis prophylaxis: oral antibiotics and lyophilized enterobacteria vs oral immunoglobulins. Acta Paediatr Suppl 396:86\u201390","journal-title":"Acta Paediatr Suppl"},{"key":"422_CR61","first-page":"45","volume":"12","author":"A Fateh-Moghadam","year":"1984","unstructured":"Fateh-Moghadam A, Wick M, Simon H (1984) Comparative protein analytic studies of various intravenous 7S-immunoglobulin preparations [article in German]. Immun Infekt 12:45\u201350","journal-title":"Immun Infekt"},{"key":"422_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0167-5699(86)90168-4","volume":"7","author":"A Feinstein","year":"1986","unstructured":"Feinstein A, Richardson N, Taussig MI (1986) Immunoglobulin flexibility in complement activation. Immunol Today 7:169\u2013174","journal-title":"Immunol Today"},{"key":"422_CR63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jinf.2014.06.006","volume":"69","author":"C Feldman","year":"2014","unstructured":"Feldman C, Anderson R (2014) Current and new generation pneumococcal vaccines. J Infect 69:309\u2013325","journal-title":"J Infect"},{"key":"422_CR64","first-page":"133","volume":"XVII","author":"I Flenker","year":"1977","unstructured":"Flenker I (1977) Einsatz von Gamma-Globulin bei bakteriellen Meningitiden. Die gelben Hefte XVII:133\u2013135","journal-title":"Die gelben Hefte"},{"key":"422_CR65","first-page":"112","volume":"97","author":"A Fortelny","year":"1985","unstructured":"Fortelny A, Heinz R, Waldner R et al (1985) Clinical effects of high-dose immunoglobulin therapy in adults with idiopathic thrombocytopenic purpura [article in German]. Wien Klin Wochenschr 97:112\u2013115","journal-title":"Wien Klin Wochenschr"},{"key":"422_CR66","first-page":"CD001816","volume":"1","author":"J Foster","year":"2004","unstructured":"Foster J, Seth R, Cole MJ (2004) Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth-weight neonates. Cochrane Database Syst Rev 1:CD001816","journal-title":"Cochrane Database Syst Rev"},{"key":"422_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.11.020","volume":"194","author":"S Fuchs","year":"2008","unstructured":"Fuchs S, Feferman T, Meidler R et al (2008) A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol 194:89\u201396","journal-title":"J Neuroimmunol"},{"key":"422_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","volume":"126","author":"A Gardulf","year":"2008","unstructured":"Gardulf A, Borte M, Ochs HD et al (2008) Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 126:81\u201388","journal-title":"Clin Immunol"},{"key":"422_CR69","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.it.2013.04.002","volume":"34","author":"B Geering","year":"2013","unstructured":"Geering B, Stoeckle C, Conus S et al (2013) Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends Immunol 34:398\u2013409","journal-title":"Trends Immunol"},{"key":"422_CR70","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand EW (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367:2015\u20132025","journal-title":"N Engl J Med"},{"key":"422_CR71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0165-5876(96)01472-3","volume":"39","author":"V Giraudi","year":"1997","unstructured":"Giraudi V, Riganti C, Torales MR et al (1997) Upper respiratory infections in children: response to endonasal administration of IGA. Int J Pediatr Otorhinolaryngol 39:103\u2013110","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"422_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00392-014-0750-y","volume":"104","author":"CA Gleissner","year":"2015","unstructured":"Gleissner CA, Erbel C, Haeussler J et al (2015) Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clin Res Cardiol 104:13\u201322","journal-title":"Clin Res Cardiol"},{"key":"422_CR73","first-page":"211","volume":"32","author":"A Greinacher","year":"1994","unstructured":"Greinacher A, M\u00f6ckel M, Mueller-Eckhardt C (1994) Suppression of FcRII by intravenously administered IgG is dependent of preparation procedures of immunoglobulins [article in German]. Beitr Infusionsther Transfusionsmed 32:211\u2013213","journal-title":"Beitr Infusionsther Transfusionsmed"},{"key":"422_CR74","first-page":"115","volume":"9","author":"PH Gronski","year":"1982","unstructured":"Gronski PH, Kanzy T, L\u00fcben EJ et al (1982) S-sulfonation as a reversible chemical modification of immunoglobulin [article in German]. Beitr Infusionther Klin Ernahr 9:115\u2013125","journal-title":"Beitr Infusionther Klin Ernahr"},{"key":"422_CR75","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1423-0410.1983.tb01899.x","volume":"45","author":"P Gronski","year":"1983","unstructured":"Gronski P, Hofstaetter T, Kanzy EJ et al (1983) S-Sulfonation: a reversible chemical modification of human immunoglobulin permitting intravenous application. Vox Sang 45:144\u2013154","journal-title":"Vox Sang"},{"issue":"Suppl 1","key":"422_CR76","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1007\/s10875-014-0025-4","volume":"34","author":"C Gr\u00f6nwall","year":"2014","unstructured":"Gr\u00f6nwall C, Silverman GJ (2014) Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol 34(Suppl 1):S12\u2013S21","journal-title":"J Clin Immunol"},{"key":"422_CR77","doi-asserted-by":"publisher","first-page":"e21246","DOI":"10.1371\/journal.pone.0021246","volume":"6","author":"T Guhr","year":"2011","unstructured":"Guhr T, Bloem J, Derksen NI et al (2011) Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 6:e21246","journal-title":"PLoS One"},{"key":"422_CR78","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.transci.2012.03.022","volume":"46","author":"\u00c9 Haddad","year":"2012","unstructured":"Haddad \u00c9, Barnes D, Kafal A (2012) Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci 46:315\u2013321","journal-title":"Transfus Apher Sci"},{"key":"422_CR79","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2249.1995.tb08359.x","volume":"101","author":"KN Haque","year":"1995","unstructured":"Haque KN, Remo C, Bahakim H (1995) Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol 101:328\u2013333","journal-title":"Clin Exp Immunol"},{"key":"422_CR80","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","volume":"16","author":"T Harbo","year":"2009","unstructured":"Harbo T, Andersen H, Hess A et al (2009) Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16:631\u2013638","journal-title":"Eur J Neurol"},{"key":"422_CR81","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1600-6143.2008.02524.x","volume":"9","author":"A Haririan","year":"2009","unstructured":"Haririan A, Nogueira J, Kukuruga D et al (2009) Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 9:536\u2013542","journal-title":"Am J Transplant"},{"key":"422_CR82","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00006454-199805000-00004","volume":"17","author":"T Heikinnen","year":"1998","unstructured":"Heikinnen T, Rouhola A, Ruuskanen O et al (1998) Intranasally administered immunoglobulin for the prevention of rhinitis in children. Pediatr Infect Dis J 17:367\u2013372","journal-title":"Pediatr Infect Dis J"},{"key":"422_CR83","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3109\/00365549309008580","volume":"25","author":"P Hemmingsson","year":"1993","unstructured":"Hemmingsson P, Hammarstr\u00f6m L (1993) Nasal administration of immunoglobulin as effective prophylaxis against infections in elite cross-country skiers. Scand J Infect Dis 25:783\u2013785","journal-title":"Scand J Infect Dis"},{"key":"422_CR84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1423-0410.1983.tb01900.x","volume":"45","author":"T Hofstaetter","year":"1983","unstructured":"Hofstaetter T, Gronski P, Kanzy EJ et al (1983) S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application. II Effect on Fc-mediated effector functions. Vox Sang 45:155\u2013165","journal-title":"Vox Sang"},{"key":"422_CR85","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V et al (2008) Intravenous immune globulin (10\u00a0% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136\u2013144","journal-title":"Lancet Neurol"},{"key":"422_CR86","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228\u20131231","journal-title":"Lancet"},{"key":"422_CR87","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1100441","volume":"365","author":"P Brocklehurst","year":"2011","unstructured":"INIS Collaborative Group, Brocklehurst P, Farrell B et al (2011) Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 365:1201\u20131211","journal-title":"N Engl J Med"},{"key":"422_CR88","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clim.2011.08.003","volume":"141","author":"AC Issekutz","year":"2011","unstructured":"Issekutz AC, Rowter D, MacMillan HF (2011) Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-\u03b1-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration. Clin Immunol 141:187\u2013196","journal-title":"Clin Immunol"},{"key":"422_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000001027","author":"F Ius","year":"2015","unstructured":"Ius F, Sommer W, Kieneke D et al (2015) IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation. Transplantation. doi: 10.1097\/tp.0000000000001027","journal-title":"Transplantation"},{"key":"422_CR90","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bcp.2011.05.018","volume":"82","author":"C Jandus","year":"2011","unstructured":"Jandus C, Simon HU, von Gunten S (2011) Targeting Siglecs\u2014a novel pharmacological strategy for immuno- and glycotherapy. Biochem Pharmacol 82:323\u2013332","journal-title":"Biochem Pharmacol"},{"key":"422_CR91","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus C, Boligan KF, Chijioke O et al (2014) Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 124:1810\u20131820","journal-title":"J Clin Invest"},{"key":"422_CR92","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1172\/JCI42695","volume":"120","author":"EN Janoff","year":"2010","unstructured":"Janoff EN, Frank DN (2010) Pathogen-specific antibodies: codependent no longer. J Clin Invest 120:1039\u20131042","journal-title":"J Clin Invest"},{"key":"422_CR93","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1172\/JCI6310","volume":"104","author":"EN Janoff","year":"1999","unstructured":"Janoff EN, Fasching C, Orenstein JM et al (1999) Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest 104:1139\u20131147","journal-title":"J Clin Invest"},{"key":"422_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.bmt.1701821","volume":"24","author":"JE Johansson","year":"1999","unstructured":"Johansson JE, Ekamn T (1999) Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Bone Marrow Transplant 24:35\u201339","journal-title":"Bone Marrow Transplant"},{"key":"422_CR95","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/IAI.63.8.3166-3173.1995","volume":"63","author":"S Johnson","year":"1995","unstructured":"Johnson S, Sypura WD, Gerding DN et al (1995) Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun 63:3166\u20133173","journal-title":"Infect Immun"},{"key":"422_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","volume":"142","author":"S Jolles","year":"2005","unstructured":"Jolles S, Sewell WA, Misbah SA (2005) Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142:1\u201311","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 1","key":"422_CR97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/cei.12555","volume":"178","author":"S Jolles","year":"2014","unstructured":"Jolles S, Jordan SC, Orange JS et al (2014) Immunoglobulins: current understanding and future directions. Clin Exp Immunol 178(Suppl 1):163\u2013168","journal-title":"Clin Exp Immunol"},{"key":"422_CR98","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Ravetch J (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670\u2013673","journal-title":"Science"},{"key":"422_CR99","doi-asserted-by":"publisher","first-page":"e37243","DOI":"10.1371\/journal.pone.0037243","volume":"7","author":"F K\u00e4sermann","year":"2012","unstructured":"K\u00e4sermann F, Boerema DJ, R\u00fcegsegger M et al (2012) Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 7:e37243","journal-title":"PLoS One"},{"key":"422_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1172\/JCI118488","volume":"97","author":"S Kaveri","year":"1996","unstructured":"Kaveri S, Vassilev T, Hurez V et al (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97:865\u2013869","journal-title":"J Clin Invest"},{"key":"422_CR101","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747\u2013755","journal-title":"N Engl J Med"},{"key":"422_CR102","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/bj2710285","volume":"271","author":"M Kerr","year":"1990","unstructured":"Kerr M (1990) The structure and function of human IgA. Biochem J 271:285\u2013296","journal-title":"Biochem J"},{"key":"422_CR103","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","volume":"5","author":"J Kerr","year":"2014","unstructured":"Kerr J, Quinti I, Eibl M et al (2014) Is dosing of therapeutic immunoglobulins optimal? A review of a 3-decade long debate in Europe. Front Immunol 5:629","journal-title":"Front Immunol"},{"key":"422_CR104","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","volume":"179","author":"A Kessel","year":"2007","unstructured":"Kessel A, Ammuri H, Peri R et al (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179:5571\u20135575","journal-title":"J Immunol"},{"key":"422_CR105","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1002\/eji.200737655","volume":"37","author":"K Kikuno","year":"2007","unstructured":"Kikuno K, Kang DW, Tahara K et al (2007) Unusual biochemical features and follicular dendritic cell expression of human Fc\u03b1\/\u03bc receptor. Eur J Immunol 37:3540\u20133550","journal-title":"Eur J Immunol"},{"key":"422_CR106","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1423-0410.1962.tb03274.x","volume":"7","author":"P Kistler","year":"1962","unstructured":"Kistler P, Nitschman H (1962) Large scale production of human plasma fractions: eight years experience with the alcohol fractionation procedure. Vox Sang 7:414\u2013424","journal-title":"Vox Sang"},{"key":"422_CR107","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1134\/S0006297911050038","volume":"76","author":"VB Klimovich","year":"2011","unstructured":"Klimovich VB (2011) IgM and its receptors: structural and functional aspects. Biochem Moscow 76:534\u2013549","journal-title":"Biochem Moscow"},{"key":"422_CR108","first-page":"199","volume":"6","author":"HG Klingemann","year":"1990","unstructured":"Klingemann HG, Barnett MJ, Reece DE et al (1990) Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease. Bone Marrow Transplant 6:199\u2013202","journal-title":"Bone Marrow Transplant"},{"key":"422_CR109","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.molimm.2010.05.011","volume":"47","author":"M Kojouharova","year":"2010","unstructured":"Kojouharova M, Reid K, Gadjeva M (2010) New insights into the molecular mechanisms of classical complement activation. Mol Immunol 47:2154\u20132160","journal-title":"Mol Immunol"},{"key":"422_CR110","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","volume":"12","author":"I Krause","year":"2002","unstructured":"Krause I, Wu R, Sherer Y et al (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations\u2014a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfusion Med 12:133\u2013139","journal-title":"Transfusion Med"},{"key":"422_CR111","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3201\/eid2103.141838","volume":"21","author":"TR Kreil","year":"2015","unstructured":"Kreil TR (2015) Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis 21:521\u2013523","journal-title":"Emerg Infect Dis"},{"key":"422_CR112","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1189\/jlb.69.4.522","volume":"69","author":"A Lardner","year":"2001","unstructured":"Lardner A (2001) The effects of extracellular pH on immune function. J Leukoc Biol 69:522\u2013530","journal-title":"J Leukoc Biol"},{"key":"422_CR113","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1182\/blood-2012-03-415695","volume":"119","author":"D Leontyev","year":"2012","unstructured":"Leontyev D, Katsman Y, Branch DR (2012a) Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fc\u03b3 receptor for the amelioration of experimental ITP. Blood 119:5261\u20135264","journal-title":"Blood"},{"key":"422_CR114","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/j.1537-2995.2011.03517.x","volume":"52","author":"D Leontyev","year":"2012","unstructured":"Leontyev D, Katsman Y, Ma XZ et al (2012b) Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52:1799\u20131805","journal-title":"Transfusion"},{"key":"422_CR115","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li S, Rouphael N, Duraisingham S et al (2014) Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15:195\u2013204","journal-title":"Nat Immunol"},{"key":"422_CR116","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1055\/s-2007-972838","volume":"17","author":"K Lindberg","year":"1996","unstructured":"Lindberg K, Berglund B (1996) Effect of treatment with nasal IgA on the incidence of infectious disease in world-class canoeists. Int J Sports Med 17:235\u2013238","journal-title":"Int J Sports Med"},{"key":"422_CR117","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1074\/jbc.M112.410811","volume":"288","author":"S Longet","year":"2013","unstructured":"Longet S, Miled S, L\u00f6tscher M et al (2013) Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J Biol Chem 288:4085\u20134094","journal-title":"J Biol Chem"},{"key":"422_CR118","doi-asserted-by":"publisher","first-page":"21617","DOI":"10.1074\/jbc.M114.549139","volume":"289","author":"S Longet","year":"2014","unstructured":"Longet S, Vonarburg C, L\u00f6tscher M et al (2014) Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen. J Biol Chem 289:21617\u201321626","journal-title":"J Biol Chem"},{"key":"422_CR119","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12016-013-8375-x","volume":"46","author":"AG Louis","year":"2014","unstructured":"Louis AG, Gupta S (2014) Primary selective IgM deficiency: an ignored immunodeficiency. Clin Rev Allergy Immunol 46:104\u2013111","journal-title":"Clin Rev Allergy Immunol"},{"key":"422_CR120","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V88.1.184.184","volume":"88","author":"H Lutz","year":"1996","unstructured":"Lutz H, Stammler P, Jelezarova E et al (1996) High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88:184\u2013193","journal-title":"Blood"},{"key":"422_CR121","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejogrb.2004.03.009","volume":"117","author":"IZ MacKenzie","year":"2004","unstructured":"MacKenzie IZ, Bichler J, Mason GC et al (2004) Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstet Gynecol Reprod Biol 117:154\u2013161","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"Suppl 1","key":"422_CR122","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1007\/s10875-012-9752-6","volume":"33","author":"MS Maddur","year":"2013","unstructured":"Maddur MS, Sharma M, Hegde P et al (2013) Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J Clin Immunol 33(Suppl 1):S62\u2013S66","journal-title":"J Clin Immunol"},{"key":"422_CR123","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0891-5849(98)00130-0","volume":"25","author":"L Margiloff","year":"1998","unstructured":"Margiloff L, Chaplia L, Chow A et al (1998) Metal-catalyzed oxidation of immunoglobulin G impairs Fc receptor-mediated binding to macrophages. Free Radic Biol Med 25:780\u2013785","journal-title":"Free Radic Biol Med"},{"key":"422_CR124","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ene.12080","volume":"20","author":"LH Markvardsen","year":"2013","unstructured":"Markvardsen LH, Debost JC, Harbo T et al (2013) Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 20:836\u2013842","journal-title":"Eur J Neurol"},{"key":"422_CR125","unstructured":"Martin R (1973) Einsatz von Gamma-Venin und IgM-Konzentrat bei schwerer Coli-Intoxikation mit Endotoxinschock. Die gelben Hefte, pp 186\u2013190"},{"key":"422_CR126","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.autrev.2008.03.018","volume":"7","author":"MS Matter","year":"2008","unstructured":"Matter MS, Ochsenbein AF (2008) Natural antibodies target virus\u2013antibody complexes to organized lymphoid tissue. Autoimmun Rev 7:480\u2013486","journal-title":"Autoimmun Rev"},{"key":"422_CR127","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1172\/JCI38322","volume":"120","author":"EE McClelland","year":"2010","unstructured":"McClelland EE, Nicola AE, Prados-Rosales R, Casadevall A (2010) Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 120:1355\u20131361","journal-title":"J Clin Invest"},{"key":"422_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00011-007-6213-4","volume":"57","author":"NM Mihaylova","year":"2008","unstructured":"Mihaylova NM, Dimitrov JD, Djoumerska-Alexieva IK et al (2008) Inflammation-induced enhancement of IgG immunoreactivity. Inflamm Res 57:1\u20133","journal-title":"Inflamm Res"},{"key":"422_CR129","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","volume":"21","author":"RC Monteiro","year":"2003","unstructured":"Monteiro RC, van de Winkel JG (2003) IgA Fc receptors. Annu Rev Immunol 21:177\u2013204","journal-title":"Annu Rev Immunol"},{"key":"422_CR130","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","volume":"27","author":"VS Negi","year":"2007","unstructured":"Negi VS, Elluru S, Sib\u00e9ril S et al (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27:233\u2013245","journal-title":"J Clin Immunol"},{"key":"422_CR131","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcrc.2005.03.003","volume":"20","author":"AR Neilson","year":"2005","unstructured":"Neilson AR, Burchardi H, Schneider H (2005) Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 20:239\u2013249","journal-title":"J Crit Care"},{"key":"422_CR132","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341\u2013347","journal-title":"N Engl J Med"},{"key":"422_CR133","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4049\/jimmunol.1401880","volume":"194","author":"TT Nguyen","year":"2015","unstructured":"Nguyen TT, Elsner RA, Baumgarth N (2015) Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J Immunol 194:1489\u20131502","journal-title":"J Immunol"},{"key":"422_CR134","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/hlca.19540370327","volume":"37","author":"H Nitschmann","year":"1954","unstructured":"Nitschmann H, Kistler P, Lergier W (1954) Simplified method for isolation of human albimin and G-globulin from plasma using the ethnol precipitation method. Helv Chim Acta 37:866\u2013873","journal-title":"Helv Chim Acta"},{"key":"422_CR135","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.4049\/jimmunol.156.8.3057","volume":"156","author":"A Norrby-Tegerlund","year":"1996","unstructured":"Norrby-Tegerlund A, Kaul R, Low DE et al (1996) Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 156:3057\u20133064","journal-title":"J Immunol"},{"key":"422_CR136","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1086\/317423","volume":"31","author":"A Norrby-Teglund","year":"2000","unstructured":"Norrby-Teglund A, Ihendyane N, Kansal R et al (2000) Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens. Clin Infect Dis 31:1175\u20131182","journal-title":"Clin Infect Dis"},{"key":"422_CR137","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1074\/jbc.R110.179325","volume":"286","author":"RH Oakley","year":"2011","unstructured":"Oakley RH, Cidlowski JA (2011) Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 286:3177\u20133184","journal-title":"J Biol Chem"},{"key":"422_CR138","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"H Ochs","year":"2006","unstructured":"Ochs H, Gupta S, Kiessling P et al (2006) Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26:265\u2013273","journal-title":"J Clin Immunol"},{"key":"422_CR139","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S0167-5699(00)01754-0","volume":"21","author":"AF Ochsenbein","year":"2000","unstructured":"Ochsenbein AF, Zinkernagel RM (2000) Natural antibodies and complement link innate and acquired immunity. Immunol Today 21:624\u2013630","journal-title":"Immunol Today"},{"key":"422_CR140","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","volume":"286","author":"AF Ochsenbein","year":"1999","unstructured":"Ochsenbein AF, Fehr T, Lutz C et al (1999) Control of early viral and bacterial distribution and disease by natural antibodies. Science 286:2156\u20132159","journal-title":"Science"},{"key":"422_CR141","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/eji.201444440","volume":"44","author":"S Othy","year":"2014","unstructured":"Othy S, Top\u00e7u S, Saha C et al (2014) Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur J Immunol 44:2059\u20132063","journal-title":"Eur J Immunol"},{"key":"422_CR142","first-page":"31","volume":"22","author":"B Pasquier","year":"2005","unstructured":"Pasquier B, Launay P, Kanamaru Y et al (2005) Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22:31\u201342","journal-title":"Immunity"},{"key":"422_CR143","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.clim.2010.10.010","volume":"138","author":"S Pavlovic","year":"2011","unstructured":"Pavlovic S, Zdravkovic N, Dimitrov JD et al (2011) Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin Immunol 138:162\u2013171","journal-title":"Clin Immunol"},{"key":"422_CR144","doi-asserted-by":"publisher","first-page":"ra24","DOI":"10.1126\/scisignal.2001309","volume":"4","author":"S Pfirsch-Maisonnas","year":"2011","unstructured":"Pfirsch-Maisonnas S, Aloulou M, Xu T et al (2011) Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized \u201cInhibisome\u201d clusters. Sci Signal 4:ra24","journal-title":"Sci Signal"},{"key":"422_CR1","doi-asserted-by":"crossref","unstructured":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Lancet 349:225\u2013230","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"422_CR145","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1172\/JCI107875","volume":"54","author":"AG Plaut","year":"1974","unstructured":"Plaut AG, Wistar R Jr, Capra JD (1974) Differential susceptibility of human IgA immunoglobulins to streptococcal IgA protease. J Clin Invest 54:1295\u20131300","journal-title":"J Clin Invest"},{"key":"422_CR146","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1126\/science.810892","volume":"190","author":"AG Plaut","year":"1975","unstructured":"Plaut AG, Gilbert JV, Artenstein MS et al (1975) Neisseria gonorrhoeae and Neisseria meningitidis: extracellular enzyme cleaves human immunoglobulin A. Science 190:1103\u20131105","journal-title":"Science"},{"key":"422_CR147","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijantimicag.2008.01.021","volume":"32","author":"MW Pletz","year":"2008","unstructured":"Pletz MW, Maus U, Krug N et al (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32:199\u2013206","journal-title":"Int J Antimicrob Agents"},{"key":"422_CR148","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1537-2995.1968.tb04895.x","volume":"8","author":"W Pollack","year":"1968","unstructured":"Pollack W, Gorman JG, Ereda VJ et al (1968) Results of clinical trials of RhoGAM in women. Transfusion 8:151\u2013153","journal-title":"Transfusion"},{"key":"422_CR149","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.1016\/S0021-9258(17)39372-9","volume":"260","author":"PHPM Poon","year":"1985","unstructured":"Poon PHPM, Schumaker VN (1985) Immunoglobulin M possesses two binding sites for complement subcomponent C1q, and soluble 1:1 and 2:1 complexes are formed in solution at reduced ionic strength. J Biol Chem 260:9357\u20139365","journal-title":"J Biol Chem"},{"key":"422_CR150","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00002826-200209000-00005","volume":"25","author":"R Pul","year":"2002","unstructured":"Pul R, Nguyen D, Schmitz U et al (2002) Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM\/IgA-enriched preparation. Clin Neuropharmacol 25:254\u2013259","journal-title":"Clin Neuropharmacol"},{"key":"422_CR151","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1172\/JCI82695","volume":"125","author":"I Quast","year":"2015","unstructured":"Quast I, Keller CW, Maurer MA et al (2015) Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125:4160\u20134170","journal-title":"J Clin Invest"},{"key":"422_CR152","first-page":"743","volume":"16","author":"B Rager-Zisman","year":"2014","unstructured":"Rager-Zisman B (2014) Antibody therapy to limit the spread of Ebola virus. Isr Med Assoc J 16:743","journal-title":"Isr Med Assoc J"},{"key":"422_CR153","doi-asserted-by":"publisher","first-page":"e1002071","DOI":"10.1371\/journal.ppat.1002071","volume":"7","author":"C Ramakrishna","year":"2011","unstructured":"Ramakrishna C, Newo AN, Shen YW et al (2011) Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog 7:e1002071","journal-title":"PLoS Pathog"},{"key":"422_CR154","doi-asserted-by":"publisher","DOI":"10.3205\/000103","author":"K Reinhart","year":"2010","unstructured":"Reinhart K, Brunkhorst FM, Bone HG et al (2010) Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Intensiv- und Notfallmedizin (DIVI)). Ger Med. doi: 10.3205\/000103","journal-title":"Ger Med"},{"key":"422_CR155","unstructured":"Robert P (2016) Plasma industry challenges and opportunities\u2014differences between the plasma and the pharmaceutical industries. International Plasma Proteins Congress (IPPC), Barcelona"},{"key":"422_CR156","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.4049\/jimmunol.143.12.4104","volume":"143","author":"F Rossi","year":"1989","unstructured":"Rossi F, Kazatchkine MD (1989) Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 143:4104\u20134109","journal-title":"J Immunol"},{"key":"422_CR157","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1172\/JCI109031","volume":"61","author":"T Sacks","year":"1978","unstructured":"Sacks T, Moldow CF, Craddock PR et al (1978) Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest 61:1161\u20131167","journal-title":"J Clin Invest"},{"key":"422_CR158","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10875-014-0057-9","volume":"34","author":"K Samaan","year":"2014","unstructured":"Samaan K, Levasseur MC, Decaluwe H et al (2014) SCIg vs IVIg: let\u2019s give patients the choice! J Clin Immunol 34:611\u2013614","journal-title":"J Clin Immunol"},{"key":"422_CR159","first-page":"280","volume":"19","author":"C Schaffer","year":"1998","unstructured":"Schaffer C (1998) Quality of polyvalent immunoglobulins. Results of an inquiry. Krankenhauspharmazie 19:280\u2013286","journal-title":"Krankenhauspharmazie"},{"key":"422_CR160","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1398-9995.2011.02579.x","volume":"66","author":"A Schaub","year":"2011","unstructured":"Schaub A, von Gunten S, Vogel M et al (2011) Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy 66:1030\u20131037","journal-title":"Allergy"},{"key":"422_CR161","doi-asserted-by":"publisher","first-page":"269ra1","DOI":"10.1126\/scitranslmed.3010524","volume":"7","author":"C Schneider","year":"2015","unstructured":"Schneider C, Smith DF, Cummings RD et al (2015) The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med 7:269ra1","journal-title":"Sci Transl Med"},{"key":"422_CR162","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176\u2013189","journal-title":"Nat Rev Immunol"},{"key":"422_CR163","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.celrep.2015.09.013","volume":"13","author":"I Schwab","year":"2015","unstructured":"Schwab I, Lux A, Nimmerjahn F (2015) Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice. Cell Rep 13:610\u2013620","journal-title":"Cell Rep"},{"key":"422_CR164","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2009-12-261461","volume":"116","author":"JF S\u00e9\u00eft\u00e9","year":"2010","unstructured":"S\u00e9\u00eft\u00e9 JF, Cornec D, Renaudineau Y et al (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116:1698\u20131704","journal-title":"Blood"},{"key":"422_CR165","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"110","author":"J Seok","year":"2013","unstructured":"Seok J, Warren HS, Cuenca AG et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507\u20133512","journal-title":"Proc Natl Acad Sci USA"},{"key":"422_CR166","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jcrc.2005.06.002","volume":"20","author":"S Shafazand","year":"2005","unstructured":"Shafazand S, Colice G (2005) Putting the cart before the horse: a cautious look at the role of IgM-enriched polyclonal immunoglobulin in sepsis therapy. J Crit Care 20:249\u2013250","journal-title":"J Crit Care"},{"key":"422_CR167","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/aas.12652","volume":"60","author":"S Shmygalev","year":"2016","unstructured":"Shmygalev S, Damm M, Knels L et al (2016) IgM-enriched solution BT086 improves host defense capacity and energy store preservation in a rabbit model of endotoxemia. Acta Anaesthesiol Scand 60:502\u2013512","journal-title":"Acta Anaesthesiol Scand"},{"key":"422_CR168","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","volume":"14","author":"Y Shoenfeld","year":"2002","unstructured":"Shoenfeld Y, Rauova L, Gilburd B et al (2002) Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14:1303\u20131311","journal-title":"Int Immunol"},{"key":"422_CR169","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1034\/j.1600-065X.2003.00038.x","volume":"193","author":"HU Simon","year":"2003","unstructured":"Simon HU (2003) Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev 193:101\u2013110","journal-title":"Immunol Rev"},{"key":"422_CR170","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1034\/j.1398-9995.2003.00239.x","volume":"58","author":"HU Simon","year":"2003","unstructured":"Simon HU, Sp\u00e4th PJ (2003) IVIG\u2014mechanisms of action. Allergy 58:543\u2013552","journal-title":"Allergy"},{"key":"422_CR171","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000073716","volume":"132","author":"D Simon","year":"2003","unstructured":"Simon D, von Gunten S, Borelli S et al (2003) The interleukin-13 production by peripheral blood T cells from atopic dermatitis patients does not require CD2 costimulation. Int Arch Allergy Immunol 132:148\u2013155","journal-title":"Int Arch Allergy Immunol"},{"key":"422_CR172","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1056\/NEJM198710223171703","volume":"317","author":"DR Snydman","year":"1987","unstructured":"Snydman DR, Werner BG, Heinze-Lacey B et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049\u20131054","journal-title":"N Engl J Med"},{"key":"422_CR173","doi-asserted-by":"publisher","first-page":"984","DOI":"10.7326\/0003-4819-119-10-199311150-00004","volume":"119","author":"DR Snydman","year":"1993","unstructured":"Snydman DR, Werner BG, Dougherty NN et al (1993) Cytomegalovirus immune globulin prophylaxis in liver transplantation a randomized, double-blind, placebo-controlled trial. Ann Intern Med 119:984\u2013991","journal-title":"Ann Intern Med"},{"key":"422_CR174","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1023\/A:1009899803032","volume":"3","author":"P Sp\u00e4th","year":"1999","unstructured":"Sp\u00e4th P (1999) Structure and function of immunoglobulins. Sepsis 3:197\u2013218","journal-title":"Sepsis"},{"key":"422_CR175","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7182\/pit2014750","volume":"24","author":"PJ Sp\u00e4th","year":"2014","unstructured":"Sp\u00e4th PJ (2014) A novel use of intravenous immunoglobulin is not restricted to complement hypercatabolism because of factor H deficiency. Prog Transplant 24:120","journal-title":"Prog Transplant"},{"key":"422_CR176","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","volume":"6","author":"PJ Sp\u00e4th","year":"2015","unstructured":"Sp\u00e4th PJ, Granata G, La Marra F et al (2015) On the dark side of therapies with immunoglobulin concentrates. The adverse events. Front Immunol 6:11","journal-title":"Front Immunol"},{"key":"422_CR177","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molimm.2015.03.007","volume":"67","author":"M Stegert","year":"2015","unstructured":"Stegert M, Bock M, Trendelenburg M (2015) Clinical presentation of human C1q deficiency: how much of a lupus? Mol Immunol 67:3\u201311","journal-title":"Mol Immunol"},{"key":"422_CR178","first-page":"282","volume":"7","author":"W Stephan","year":"1969","unstructured":"Stephan W (1969) Elimination of complement fixation of \u03b3-globulin by chemical modification with \u03b2-propiolactone Z [article in German]. Klin Chem Klin Biochem 7:282\u2013286","journal-title":"Klin Chem Klin Biochem"},{"key":"422_CR179","first-page":"2090","volume":"30","author":"W Stephan","year":"1980","unstructured":"Stephan W (1980) Human i.v. immune globulin by chemical modification with \u03b2-propiolactone\u2014radiochemical study [article in German]. Arzneimittelforschung 30:2090\u20132093","journal-title":"Arzneimittelforschung"},{"key":"422_CR180","first-page":"933","volume":"35","author":"W Stephan","year":"1985","unstructured":"Stephan W, Dichtelm\u00fcller H, Schedel I (1985) Properties and efficacy of a human immunoglobulin M preparation for intravenous administration. Arzneimittelforschung 35:933\u2013936","journal-title":"Arzneimittelforschung"},{"key":"422_CR181","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.biologicals.2008.07.002","volume":"36","author":"ER Stiehm","year":"2008","unstructured":"Stiehm ER, Keller MA, Vyas GN (2008) Preparation and use of therapeutic antibodies primarily of human origin. Biologicals 36:363\u2013374","journal-title":"Biologicals"},{"key":"422_CR182","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nchembio.1525","volume":"10","author":"SR Stowell","year":"2014","unstructured":"Stowell SR, Arthur CM, McBride R et al (2014) Microbial glycan microarrays define key features of host-microbial interactions. Nat Chem Biol 10:470\u2013476","journal-title":"Nat Chem Biol"},{"key":"422_CR184","unstructured":"St\u00fcbner (1979) Resistente E. coli St\u00e4mme: Kombination von Immunglobulinen und Antibiotikum wirksam. Die gelben Hefte, pp 77\u201382"},{"issue":"Suppl 1","key":"422_CR185","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1007\/s10875-012-9842-5","volume":"33","author":"N Svetlicky","year":"2013","unstructured":"Svetlicky N, Ortega-Hernandez OD, Mouthon L et al (2013) The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol 33(Suppl 1):S27\u2013S32","journal-title":"J Clin Immunol"},{"key":"422_CR186","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V85.2.548.548","volume":"85","author":"P Terness","year":"1995","unstructured":"Terness P, Kirschfink M, Navolan D et al (1995) Striking inverse correlation between IgG anti-F(ab\u2019)2 and autoantibody production in patients with cold agglutination. Blood 85:548\u2013551","journal-title":"Blood"},{"key":"422_CR187","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.4049\/jimmunol.170.9.4564","volume":"170","author":"MC Thurnheer","year":"2003","unstructured":"Thurnheer MC, Zuercher AW, Cebra JJ et al (2003) B1 cells contribute to serum IgM, but not to intestinal IgA, production in gnotobiotic ig allotype chimeric mice. J Immunol 170:4564\u20134571","journal-title":"J Immunol"},{"key":"422_CR188","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0140-6736(93)90477-X","volume":"341","author":"B Tjellstr\u00f6m","year":"1993","unstructured":"Tjellstr\u00f6m B, Stenhammar L, Eriksson S et al (1993) Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 341:701\u2013702","journal-title":"Lancet"},{"key":"422_CR189","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fimmu.2015.00197","volume":"6","author":"AS Tjon","year":"2015","unstructured":"Tjon AS, van Gent R, Geijtenbeek TB et al (2015) Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye. Front Immunol 6:197","journal-title":"Front Immunol"},{"key":"422_CR190","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood-2012-11-468264","volume":"122","author":"J Trinath","year":"2013","unstructured":"Trinath J, Hegde P, Sharma M et al (2013) Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122:1419\u20131427","journal-title":"Blood"},{"key":"422_CR191","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1194\/jlr.P054569","volume":"56","author":"D Tsiantoulas","year":"2015","unstructured":"Tsiantoulas D, Perkmann T, Afonyushkin T et al (2015) Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. J Lipid Res 56:440\u2013448","journal-title":"J Lipid Res"},{"key":"422_CR192","unstructured":"Tunn U (1976) Einsatz von Immunglobulin G und M bei obstruktiver septischer Pyelonephritis. Die Gelben Hefte, pp 79\u201381"},{"key":"422_CR193","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.intimp.2014.01.007","volume":"19","author":"R van Gent","year":"2014","unstructured":"van Gent R, Jaadar H, Tjon AS et al (2014) T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process. Int Immunopharmacol 19:142\u2013144","journal-title":"Int Immunopharmacol"},{"key":"422_CR194","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1468-1331.2006.01466.x","volume":"13","author":"IN Van Schaik","year":"2006","unstructured":"Van Schaik IN, Bouche P, Illa I et al (2006) European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 13:802\u2013808","journal-title":"Eur J Neurol"},{"key":"422_CR195","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fimmu.2013.00004","volume":"4","author":"J Vas","year":"2013","unstructured":"Vas J, Gr\u00f6nwall C, Silverman G (2013) Fundamental roles of the innate-like repertoire of natural antibodies in immune homeostasis. Front Immunol 4:4","journal-title":"Front Immunol"},{"key":"422_CR196","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ana.24345","volume":"77","author":"LM Villar","year":"2015","unstructured":"Villar LM, Costa-Frossard L, Masterman T et al (2015) Lipid-specific IgM bands in CSF associated with a reduced risk of developing PML during treatment with natalizumab. Ann Neurol 77:447\u2013457","journal-title":"Ann Neurol"},{"key":"422_CR197","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cei.12550","volume":"178","author":"S von Gunten","year":"2014","unstructured":"von Gunten S (2014) Protein-glycan interactions as targets of intravenous\/subcutaneous immunoglobulin (IVIg\/SCIg) preparations. Clin Exp Immunol 178:151\u2013152","journal-title":"Clin Exp Immunol"},{"key":"422_CR198","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1196\/annals.1443.011","volume":"1143","author":"S von Gunten","year":"2008","unstructured":"von Gunten S, Bochner BS (2008) Basic and clinical immunology of Siglecs. Ann N Y Acad Sci 1143:61\u201382","journal-title":"Ann N Y Acad Sci"},{"key":"422_CR199","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1096\/fj.05-5401hyp","volume":"20","author":"S von Gunten","year":"2006","unstructured":"von Gunten S, Simon HU (2006) Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes. FASEB J 20:601\u2013605","journal-title":"FASEB J"},{"key":"422_CR200","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4161\/auto.3436","volume":"3","author":"S von Gunten","year":"2007","unstructured":"von Gunten S, Simon HU (2007) Autophagic-like cell death in neutrophils induced by autoantibodies. Autophagy 3:67\u201368","journal-title":"Autophagy"},{"key":"422_CR201","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.autrev.2008.03.015","volume":"7","author":"S von Gunten","year":"2008","unstructured":"von Gunten S, Simon HU (2008) Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 7:453\u2013456","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"422_CR202","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1007\/s10875-010-9411-8","volume":"30","author":"S von Gunten","year":"2010","unstructured":"von Gunten S, Simon HU (2010) Cell death modulation by intravenous immunoglobulin. J Clin Immunol 30(Suppl 1):S24\u2013S30","journal-title":"J Clin Immunol"},{"key":"422_CR203","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-4614-3461-0_12","volume":"750","author":"S von Gunten","year":"2012","unstructured":"von Gunten S, Simon HU (2012) Granulocyte death regulation by naturally occurring autoantibodies. Adv Exp Med Biol 750:157\u2013172","journal-title":"Adv Exp Med Biol"},{"key":"422_CR204","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1182\/blood-2004-10-4112","volume":"106","author":"S von Gunten","year":"2005","unstructured":"von Gunten S, Yousefi S, Seitz M et al (2005) Siglec-9 transduces apoptotic and non-apoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment. Blood 106:1423\u20131431","journal-title":"Blood"},{"key":"422_CR205","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","volume":"108","author":"S von Gunten","year":"2006","unstructured":"von Gunten S, Schaub A, Vogel M et al (2006) Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108:4255\u20134259","journal-title":"Blood"},{"key":"422_CR206","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jaci.2007.01.023","volume":"119","author":"S von Gunten","year":"2007","unstructured":"von Gunten S, Vogel M, Schaub A et al (2007) Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 119:1005\u20131011","journal-title":"J Allergy Clin Immunol"},{"key":"422_CR207","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/SHK.0b013e3181a1bc98","volume":"32","author":"S von Gunten","year":"2009","unstructured":"von Gunten S, Jakob S, Geering B et al (2009a) Different patterns of Siglec-9-mediated neutrophil death responses in septic shock. Shock 32:386\u2013392","journal-title":"Shock"},{"issue":"1268\u20131276","key":"422_CR208","first-page":"e15","volume":"123","author":"S von Gunten","year":"2009","unstructured":"von Gunten S, Smith DF, Cummings RD et al (2009b) Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. J Allergy Clin Immunol 123(1268\u20131276):e15","journal-title":"J Allergy Clin Immunol"},{"key":"422_CR209","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/all.12312","volume":"68","author":"S von Gunten","year":"2013","unstructured":"von Gunten S, Cortinas-Elizondo F, Kollarik M et al (2013) Mechanisms and potential therapeutic targets in allergic inflammation: recent insights. Allergy 68:1487\u20131498","journal-title":"Allergy"},{"key":"422_CR210","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nri3401-c1","volume":"14","author":"S von Gunten","year":"2014","unstructured":"von Gunten S, Shoenfeld Y, Blank M et al (2014) IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol 14:349","journal-title":"Nat Rev Immunol"},{"key":"422_CR211","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1182\/blood.V98.6.1802","volume":"98","author":"FA Wagener","year":"2001","unstructured":"Wagener FA, Eggert A, Boerman OC et al (2001) Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 98:1802\u20131811","journal-title":"Blood"},{"key":"422_CR212","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","volume":"32","author":"R Wasserman","year":"2012","unstructured":"Wasserman R (2012) Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol 32:1153\u20131164","journal-title":"J Clin Immunol"},{"key":"422_CR213","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.4049\/jimmunol.1400028","volume":"193","author":"M Wehrli","year":"2014","unstructured":"Wehrli M, Cortinas-Elizondo F, Hlushchuk R et al (2014) Human IgA Fc receptor Fc\u03b1RI (CD89) triggers different forms of neutrophil death depending on the inflammatory microenvironment. J Immunol 193:5649\u20135659","journal-title":"J Immunol"},{"key":"422_CR214","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1073\/pnas.94.5.1902","volume":"94","author":"M Welschof","year":"1997","unstructured":"Welschof M, Terness P, Kipriyanov SM et al (1997) The antigen-binding domain of a human IgG-anti-F(ab\u2032)2 autoantibody. Proc Natl Acad Sci USA 94:1902\u20131907","journal-title":"Proc Natl Acad Sci USA"},{"key":"422_CR215","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.rmed.2015.03.008","volume":"109","author":"T Welte","year":"2015","unstructured":"Welte T, Dellinger RP, Ebelt H et al (2015) Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation\u2014the CIGMA study. Resp Med 109:758\u2013767","journal-title":"Resp Med"},{"key":"422_CR216","doi-asserted-by":"publisher","first-page":"10930","DOI":"10.1073\/pnas.97.20.10930","volume":"97","author":"AD Wentworth","year":"2000","unstructured":"Wentworth AD, Jones LH, Wentworth P et al (2000) Antibodies have the intrinsic capacity to destroy antigens. Proc Natl Acad Sci USA 97:10930\u201310935","journal-title":"Proc Natl Acad Sci USA"},{"key":"422_CR217","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1126\/science.1077642","volume":"298","author":"P Wentworth Jr","year":"2002","unstructured":"Wentworth P Jr, McDunn JE, Wentworth AD et al (2002) Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science 298:2195\u20132199","journal-title":"Science"},{"key":"422_CR218","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1097\/01.CCM.0000297164.40980.F0","volume":"35","author":"K Werdan","year":"2007","unstructured":"Werdan K (2007) Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med 35:2852\u20132854","journal-title":"Crit Care Med"},{"key":"422_CR219","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.V83.5.1278.1278","volume":"83","author":"H Wolf","year":"1994","unstructured":"Wolf H, Fischer M, Puhringer H et al (1994) Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes. Blood 83:1278\u20131288","journal-title":"Blood"},{"key":"422_CR220","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1046\/j.1365-2249.1996.d01-793.x","volume":"105","author":"HM Wolf","year":"1996","unstructured":"Wolf HM, Hauber I, Gulle H et al (1996) Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc\u03b1R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-\u03b1) and IL-6 in human monocytes. Clin Exp Immunol 105:537\u2013543","journal-title":"Clin Exp Immunol"},{"key":"422_CR221","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/path.1877","volume":"208","author":"JM Woof","year":"2006","unstructured":"Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity. J Pathol 208:270\u2013282","journal-title":"J Pathol"},{"key":"422_CR222","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaneurol.2015.2188","volume":"72","author":"B Wootla","year":"2015","unstructured":"Wootla B, Watzlawik JO, Warrington AE et al (2015) Naturally occurring monoclonal antibodies and their therapeutic potential for neurologic diseases. JAMA Neurol 72:1346\u20131353","journal-title":"JAMA Neurol"},{"key":"422_CR223","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jmb.2013.02.006","volume":"425","author":"X Yu","year":"2013","unstructured":"Yu X, Vasiljevic S, Mitchell DA et al (2013) Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 425:1253\u20131258","journal-title":"J Mol Biol"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-016-0422-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00005-016-0422-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-016-0422-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:48:52Z","timestamp":1704228532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00005-016-0422-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":222,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s00005-016-0422-x","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,16]]},"assertion":[{"value":"19 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}